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ABSTRACT
Background: The apparent success of immunotherapy depends on the duration of follow up,
sometimes with little evidence of efficacy during the first 4 to 8 months and often some degree
of “pseudoprogression”. Differentiating transient pseudoprogression from true progression that
would require a change in therapy can be challenging. The present study uses mathematical
modeling and simulation to account for the unique kinetics and delayed clinical effects of
immunotherapy and suggests improved approaches to predict efficacy and patient response from
imaging studies.
Methods: A mathematical model of tumor cell-immunocyte interaction is exercised to simulate a
large number of individual patients and to derive surrogate endpoints for success or failure from
the ratio of tumor diameter at 2, 4, 6, 8, 10, or 12 months follow up to initial tumor diameter.
The simplified predator-prey model includes 4 lumped parameters: net tumor growth rate, g;
immune cell killing efficiency, k; immune cell signaling, ; and immune cell half-life decay, μ.
Differential equations, dT/dt = gT – kL and dL/dt = LT – μL, for numbers of tumor cells, T,
(the prey) and immunocytes, L, (the predators) are solved numerically as functions of time, t ,
with ranges of g, k, , and initial conditions estimated from clinically available data. Tumor
diameters, d, are proportional to the cube root of T + L. Apparent progression is defined when
the time-varying diameter ratio, d/d0, exceeds a pre-defined, adjustable threshold. True
progression is defined as d/d0 > 1 at 24 months follow up or T/T0 > 10 at any time.
Results: Depending on initial conditions, the model equations predict either simple or complex
dynamics, including cyclic increases in tumor cell numbers prior to a population crash to zero,
apparent cure with late recurrence, and better long-term outcome with initially smaller
lymphocyte numbers. Simulations of 4000 such complex cases show that d/d0 > 1.0 at 2 to 6
months is a poor predictor of true progression, and often signals pseudoprogression. However,
raising the bar or threshold for defining progressive disease from d/d0 > 1.0 to d/d0 > 2.0 during
the first 6 months of immunotherapy and lowering the bar to d/d0 > 0.5 after 6 months can
eliminate most instances of pseudoprogression and lead to better over-all outcomes.
Conclusions: Mathematical models can account for the complex dynamics of immune-tumor
cell interactions that make accurate clinical decisions to continue or discontinue treatment
difficult. The present model and approach can be adapted and calibrated to data for different
types and stages of cancer and help to optimize treatment success.
Keywords: agent-based model, checkpoint inhibitors, classifier, cutoff, delayed response,
immune modulation, iRECIST guidelines, kinetics, optimization, predator-prey,
pseudoprogression, response criteria, T-cell response, tumor infiltrating lymphocytes
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INTRODUCTION
Kinetics of conventional chemotherapy for cancer are fundamentally different from those of
immunotherapy(3, 33, 42). In conventional chemotherapy cell kill happens initially and rapidly,
until most susceptible cells are killed or toxic side effects supervene. Toxicity to normal tissues
is severe and dose related, and the maximal therapeutic effect happens very near the maximum
tolerated dose. Both therapeutic and toxic effects are related to tissue and blood concentrations
of the drug, as described by classical pharmacokinetics. These features are very much different
from those of immunotherapy for cancer, as summarized, for example, by Hoos(21).
In immunotherapy treatment effect is not proportional to toxicity, dose, schedule, or blood levels
of drug. The optimal biologic dose is often not the maximum tolerated dose. Cell kill grows
exponentially with time, as immunocyte numbers grow, beginning at a low level and ultimately
reaching a crescendo with a sudden crash in tumor cell numbers. Early tumor shrinkage is not a
consistent predictor of survival. Instead, clinical benefits can be delayed and can occur after an
apparent increase in tumor tissue volume, which would be classically characterized as
progression, and which would likely lead to discontinuation or to change in approach before any
benefits are realized. This initial surge in tumor burden, followed by tumor shrinkage, has been
termed “pseudoprogression”(7, 33).
Such differences in kinetics and toxicity require a new therapeutic mindset in evaluating whether
a treatment is working(3), as well as a new conceptual approach to clinical trial design(18, 22).
In particular, determining the end point of successful therapy may require more patience, more
tolerance of modest early tumor growth, and more time for observation to determine if the
immunotherapy is actually working. Such tolerance of continued tumor growth is concerning for
physicians and patients accustomed to ordinary chemotherapy. Better knowledge of the kinetics
of immunotherapy can help both physicians and patients understand the delayed nature of tumor
necrosis in a course of immunotherapy and avoid the temptation to quit too soon.
Accordingly, there is a need for new guidelines to distinguish temporary progression from
ultimate progression in immunotherapy of cancer, both in clinical trials and in daily clinical
practice. Already, the virtues of such innovative guidelines have been discussed(36) in terms of
“raising the bar” for the definition of progressive disease in trials of immunotherapy in order to
better identify patients with previously unrecognized benefit, despite delayed responses.
Although cancer biology and immune system biology are exceedingly complex(4), in some cases
simplifying such a problem in an abstract way can make it easier to solve. At zero risk to
patients and essentially zero cost, mathematical models can describe cell kinetics in a rigorous,
quantitative way(15, 24). By focusing on crucial factors and deliberately disregarding secondary
effects, a mathematical models can provide useful descriptions of a complex biological
processes. Accordingly, the goal of the present study is to examine results of mathematical
simulations of immunotherapy for cancer in large numbers of different patients to identify
improved predictors of ultimate outcome, despite pseudoprogression.
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METHODS
Previously, ordinary differential equation models similar to those used in ecology(6) and
epidemiology, in which cells are considered as individuals in interacting populations, have led to
important insights for cancer research and clinical practice(2, 15, 19, 25, 26). The present paper
describes mathematical modeling of the time histories of tumor growth and shrinkage during
immunotherapy to identify patterns during the first 12 months of follow up that distinguish
effective from futile therapy. The research methods include the following steps.
1. Implement a previously published and simplified kinetic model of immunotherapy
2. Develop a Monte Carlo technique for simulation of a large series of clinical cases, in
which imaging data for each case during the early months of follow up are correlated
with ultimate outcome at two years
3. Specify typical values of model parameters that can be modified, based on clinical
knowledge and data, for different cancer types and stages
4. Define appropriate ranges of model parameters and statistical sampling methods
5. Calculate time histories of tumor growth at 2, 4, 6, 8, 10, and 12 months follow up for
many individual patient simulations
6. Construct histograms of diameter ratios at each follow up time for cases of either ultimate
success or ultimate failure (true progression) at 24 months
7. Test possible time-varying “raised bars” for the definition of apparent progression and
determine their effect on the prediction of ultimate progression.
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Part 1. Kinetic model of immunotherapy
As previously described in detail(3) one can represent mathematically the predator-prey
dynamics of immunotherapy for a population of growing tumor cells (the prey) that are killed
upon contact with cytotoxic immune cells (the predators). Each population is considered to
function collectively. Although the actual populations of tumor and immune cells have diverse
players with distinct capabilities; at the population level, the outcome of the contest between
predators and prey can be represented in terms of the balance of power between [prey population
size  average growth rate] versus [predator population size  average killing effectiveness].
Let T denote the number of tumor cells and L denote the number of immune cells (lymphocytes
and activated macrophages). The rate of change in tumor cell numbers (dT/dt) as a function of
time, t , is increased by the net growth rate and decreased by immune mediated cell killing. The
rate of change in immune cells (dL/dt) is increased by lumped tumor-lymphocyte interactions
and signaling, and decreased by spontaneous lymphocyte death. Two equations describe the
overall population cytokinetics:
dT
dt

= gT − kL

(1)

and
dL
dt

= λTL − μL .

(2)

Constant, g , represents net tumor cell growth minus non-immune mediated cell death. Constant,
k, represents the average killing effectiveness of all immune cells in the predator “army”.
Constant,  , represents positive feedback of cell-cell signaling on lymphocyte recruiting, for
example from release of tumor antigens or from release of cytokines by active lymphocytes.
Constant, μ , represents spontaneous death and emigration of immune cells. Equation (1)
describes the net replication rate in absence of tumor immunity, minus the rate of killing by
immunocytes. Equation (2) describes the recruitment of immune cells from cell-cell signaling,
minus the spontaneous death of immune cells. As pointed out by Agur(2) the underlying kinetics
depend on three major factors: the size of the tumor cell population, T, the size of immune cell
population, L, and the strength of the interactions between the two populations, k and . The
lumped interaction term, , includes multiple effects in aggregate, for example changes
expression of histocompatibility complex antigens by tumor cells, which may weaken their
detection by cytotoxic lymphocytes, as well as the physical ability of immune cells to penetrate
the tumor, as in the case of the blood brain barrier in admitting only activated lymphocytes or
preferentially admitting immunosuppressive Treg type lymphocytes(26).

4

Initial conditions describe the state of the tumor at the time of diagnosis. T0 is the size of the
initial pre-treatment tumor cell population, and T(t)/T0 represents the fraction of the initial tumor
cell mass remaining at time, t , after treatment is begun. To specify initial conditions, the
number of lymphocytes is also normalized by the initial number of tumor cells, so that L0/T0
represents the initial immune cell population within the tumor.
Examination of limiting cases helps to clarify how the model works. When t = 0, then T = T0 .
When k = 0 (no tumor cell killing), dT/dt = gT, dT/T = gdt, and by integration, T = T0 egt with
unopposed tumor growth. When  = 0 there is initial tumor cell killing by the original L0
lymphocytes, but no recruiting of additional immune cells. In this case, the immunocytes decay
exponentially so that L = L0 e−μt , and in turn, dT/dt = gT − kL0 e−μt , with only a transient dip
in tumor cell growth.
An interesting and useful special case is that of an unstable steady-state, in which the tumor
neither grows nor shrinks in size. This condition represents a stalemate with zero net growth in
dT/T
L
either the immune cell population or the tumor population. Then dt 0 = 0 = g − k T0 , so that k
0

dL

= gT0/L0. Also, at stalemate dt = λL0 T0 − μL0 = 0, so that T0 = μ. These relationships help to
simplify estimation of model parameters from clinically available data, as shown in Part 3 below
for a generic solid tumor model. To model histories of tumor growth or shrinkage, Equations (1)
and (2) are integrated numerically using the simple Euler method, implemented, for example, in
Visual Basic code within an Excel spreadsheet, using a sufficiently small value of t , such as
0.001 day, a typical run time on a laptop computer being 0.3 sec per individual patient.

Part 2. Monte Carlo technique for simulation of a clinical trial
By accumulating a very large number of simulated cases using Equations (1) and (2) with
different parameter sets, one can use Monte Carlo simulations as a flight simulator for testing
classification rules. The values of the various model parameters in each case are selected from
probability distributions representing ranges of values expected in a particular patient population,
including both failed and successful treatments. Here, for any one simulation, a sample is
selected from a uniform random distribution ranging from a chosen lower limit to a chosen upper
limit for each parameter g, k, , mu, and T0/L0. Specification of these limits is explained in Part
4. A sample of 4000 simulated cases was sorted into classes representing “success” and “failure”
or ultimate progression. The definition of success was (T/T0 <1 and dT/dt <= 0), representing
either tumor elimination, continuing tumor shrinkage, or durable stable disease at 24-month
follow up. For clinical realism, success also required that T/T0 not exceed 10 at any time during
the simulation. This limit is in lieu of the “carrying capacity” constant, K, of Agur(26). Any
result other than success is interpreted as treatment failure or true progression.
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Part 3. Method for evaluating typical model parameters
Estimation of g. One way to estimate the tumor growth rate in a clinical setting is to assume that
typical cancers are held in check, compared to more aggressive ones, at least partially by
immune mechanisms, as suggested by clinical data on the emergence of tumors during
immunosuppressive therapy for organ transplants(13, 37), as well as by the correlations of tumor
associated lymphocyte numbers with clinical prognosis(14, 17, 27). In this case one can estimate
the net growth rate, g, in the absence of immune mediated cell killing, from the doubling time of
tumors of a given cell type in immunosuppressed patients. For minimally immunogenic tumors
dT/dt  gT, or dT/T  gdt, from which, after integration, T/T0  egt. For doubling time t2, in these
selected patients it follows that 2 ≈ egt2 , or g  ln(2)/t2  0.69/ t2. For example, if tumors of a
particular cell type in relatively immunosuppressed patients double in volume in 170 days after
diagnosis, then we would have g = 0.004/day. This value is a starting point for our
representative general model. It can be modified, as desired, for particular cancer types and
patient populations going forward.
Estimation of k. For the equilibrium condition dL/dt = 0 we must have k = g/L0. For example, if
g = 0.004 /day, and L0 = 0.001, then k = 4 tumor cells killed per lymphocyte per day. From
considerations of practical biology a lymphocyte can only kill a handful of tumor cells per
day(9). Hence values of 1 < k < 10 are reasonable.
Estimation of L0/T0. Parameter L0/T0 can be obtained from biopsies of human tissue, as
determined by quantitative microscopic analysis, flow cytometry, or histochemistry of excised
tumors or biopsy specimens. Lymphocytes are microscopically detectable in many tumors(14,
17, 27). Previous simulations(3) suggest that values of L0/T0 can vary over many orders of
magnitude and still result in successful tumor elimination by immunotherapy. Accordingly, this
parameter is important to study over a wide range of values to represent the overall variability of
cytokinetics during immunotherapy, especially in the setting of prior conventional
chemotherapy.
Estimation of μ. Normal biology and clinical experience set limits on the value of lymphocyte
decay, μ. The offset time for moderate to severe viral infections, which are combated by cellular
immunity, is on the order of about one week. The exponential decay of the induration of a PPD
(purified protein derivative) test for tuberculosis, mediated by cellular immunity, is also a few
days to one or two weeks(38). Thus in the absence of stimulation (LT = 0) we would have
dL/dt = –μL or , L/L0  e–μt . For half time t1/2, it follows that 1/2 = e−μt1/2 , or μ = ln(2)/t1/2 
0.69/ t1/2. For example, if the offset of a cellular immune response has a half-life of 7 days, then
μ  0.1/day.
Estimation of . Using the relationship that at stalemate

dL
dt

= λL0 T0 − μL0 = 0, one can get a

working estimate of  = μ/T0 . So, for T0 = 1, representing the relative initial tumor population
size as in Table 1,  is estimated as 0.1/day. In this way reasonable mid-range approximations
for parameters g, L0/T0 , μ, and k, and  can be determined from clinical data for particular types
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of tumors. In the present Monte Carlo or stochastic models, individual cases were generated by
randomly varying model parameters from the midrange values at stalemate listed in Table 1.

Table 1. Generic model parameters at stalemate with no net tumor growth,
despite an active immune system
Parameter

Value and units

Description

T0/T0
L0/T0
g
k

1
0.001
0.004/day
4/days


μ

0.1/day/tumor cell
0.1/day

Relative tumor cell count
Relative immune cell count
Tumor growth constant with minimal immune response
Immune cell killing effectiveness
(tumor cells killed/lymphocyte/day)
Immune cell signaling constant
Spontaneous half-life decay of immunocytes

Part 4. Ranges of model parameters and statistical sampling
In the present problem there is a need to focus on clinically realistic ranges of parameters g, k,
L0/T0, , and . An unrealistically wide range of parameter values, producing many obvious
successes and many obvious failures would make simulated clinical decision making falsely
easy. So, to determine if various possible decision making algorithms might be clinically useful,
one needs to test difficult to distinguish cases. The studies presented here allowed variation of
parameters over a range extending to twice the stalemate values in Table 1. Uniform probability
distributions for parameters g, k, L0/T0, , and  were used with upper and lower bounds shown
in Table 2. To span the very large range of possible values of L0/T0, covering several orders of
magnitude, sampling from a uniform distribution of the logarithm of L0/T0 was done.

Table 2. Lower and upper limits of model parameters in Monte Carlo simulations
of difficult to distinguish cases
Parameter

Lower limit and units

Upper limit and units

g
k
Log10(L0 /T0)

μ

0.001/day
0.1/day
-2
0.01 days/tumor cell
0.01/day

0.009/day
10/day
-8
0.2 days/tumor cell
0.2/day
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Part 5. Tumor diameter changes at 2, 4, 6, 8, 10, and 12 months as predictors of success or
failure
New guidelines(31) focus on changes in aggregate tumor diameter, d , vs. time as a marker for
benefit vs. progression. Tumor diameter can be estimated at follow up by a variety of medical
imaging methods. Diameter based measurements are highly precise and provide a standard
metric for immune-related response(31). The present study uses the growth ratio d/d0 as an easily
computed mathematical surrogate for average nodule diameter. Here we can translate cell
numbers into tumor size using the overall number of tumor cells, T, plus the overall number of
lymphocytic cells, L in the tumor. This sum is assumed to be directly proportional to the tumor
volume (average linear dimension cubed), and the relative diameter, d/d0 , of tumor masses at
3
follow up, so that d/d0 is computed as √(𝑇 + 𝐿)/(𝑇0 + 𝐿0 ) . Simulated data from full two-year
(24 month) treatment histories are used to find the relationship between d/d0 at 2, 4, 6, 8, 10, and
12 months and ultimate success or failure at 24 months.

Part 6. Histograms of diameter ratios for success and failure
To evaluate the effectiveness of d/d0 as a predictor of success vs. failure, histograms are created
for d/d0 data at each bi-monthly follow up time during the first year, first for all successful
treatments and then for all failed treatments. When the histograms show separation of the two
populations on the d/d0 axis, then one can set a decision threshold (“bar” or cutoff value) to
predict failure early. If the tumor diameter ratio is less than an optimized cutoff value, then
watchful waiting is in order and success is likely. However, if the tumor diameter ratio is greater
than the optimized cutoff value, then failure is more likely, and the patient is better served by a
change in treatment. The overall predictive value of this diagnostic test depends on the
separation of the distributions of d/d0 for successful and failed treatments.

Part 7. A raised bar for immunotherapy
The concept of “re-setting the bar” and for defining progressive disease has been advocated in
the iRECIST guidelines for response criteria in trials testing immunotherapeutics(36). In the
present context the bar can be time varying. As shown, for example, in Results Figure 6, the
dashed vertical lines correspond to a particular d/d0 cutoff levels at either 2, 4, 6, 8, 10, or 12
months. Optimization is done by trial and error and consideration of the value added by a simple
and memorable rule-of-thumb.
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RESULTS
Variable histories of immunotherapy
Figure 1 illustrates a variety of simulated histories of immunotherapy for the generic tumor
model of Tables 1 and 2. Variations in tumor size are represented in terms of the tumor diameter
ratio d/d0 . The middle curve, labeled 1.0X, represents the unstable equilibrium model in Table
1. Other curves represent large or small deviations from the unstable equilibrium caused by the
combined, reciprocal alteration of the two most influential model parameters, immune-tumor cell
interaction, , and tumor growth rate, g. The monotonically increasing upper curve, labeled
0.2X, represents a poor outcome scenario in which immune response parameter, , is weakened
by a factor of 0.2 and cell growth rate, g, is increased by a factor of 1/0.2 = 5.0. This curve
describes ineffective treatment with runaway tumor growth. The monotonically decreasing
lower curve, labeled 2.0X, represents a good outcome scenario, in which immune response
parameter, , is strengthened by a factor of 2.0 and cell growth rate, g, is decreased by a factor of
1/2.0 = 0.5. This curve represents highly effective treatment. These clear-cut outcomes bracket
a wide range of more complex dynamics.

2

1.5

0.2X

d/d0

0.9X
1

1.0X
1.1X

2.0X

0.5

0
0

500

1000

1500

2000

Time (days)

Figure 1. Simulated histories of tumor size in terms of diameter ratio, d/d0 , after onset of
immunotherapy. The middle curve, labeled 1.0X, represents the unstable equilibrium model
in Table 1. Monotonically increasing upper curve, labeled 0.2X, represents a bad outcome,
and monotonically decreasing bottom curve, labeled 2.0X, represents a rapid cure.
Intermediate curves represent  10% changes in both tumor growth rate and immune
signaling from the stalemate 1.0X condition.
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The curve labeled 0.9X in Figure 1 represents only a slight weakening of immune response by 10
percent and a slight increase of tumor growth by 10 percent, compared to the stalemate
conditions at 1.0X. This modest imbalance produces oscillatory behavior. There is an initial
growth in tumor cell numbers, which then provokes an increased host response after a phase
delay. This modest increase in host response in insufficient to destroy the tumor, however, and
after a period of shrinkage, it starts to grow again. This cycle is repeated until a crescendo is
reached after 1500 days or 50 months that finally provokes a sufficient immune response to
destroy the tumor. The oscillation cycle time is about 1 year, and cure is delayed for 4 cycles.
Obversely, the curve labeled 1.1X represents only a slight strengthening of the immune response
by 10 percent and a slight decrease of tumor growth by 10 percent. There is an initial decline in
tumor cell numbers, which causes a subsequent decreased host response and allows for tumor
regrowth. This cycle is repeated at 1-year intervals until a crescendo is reached after 4 years that
eliminates the tumor. These simulations illustrate how very small changes in the balance of
factors governing predator-prey dynamics can alter the time course and outcome of
immunotherapy.
In Figure 2 the interplay of tumor cells and immune cells for two such closely matched battles is
illustrated in terms of the relative tumor and immune cell numbers. T/T0 is the ratio of the tumor
cell count at the indicated time to the tumor cell count at time zero, and L/T0 is the ratio of the
lymphocyte count at the indicated time to the tumor cell count at time zero. In Figures 2(a) and
2(b) when L0/T0 = 0.0008 at time zero, the tumor can grow slightly, disturbing the equilibrium
initially and provoking a further host response cyclically. After 1500 days the lymphocyte ratio
gets just shy of the lethal level near 0.015, but a few tumor cells hang on. The tumor is not
completely dead, but the lymphocytes go into hiding. This example represents a near cure.
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Figure 2. Histories of tumor and lymphocyte cell numbers, normalized by initial tumor cell
count T0, for a representative prolonged, back-and-forth struggle between tumor cells and
immunocytes. Growing oscillations in cell numbers occur with a cycle length of roughly 1
year and a phase delay of about 1/6 cycle or 2 months.
In Figures 2(c) and 2(d) L0/T0 = 0.0012, just slightly larger than the unstable stalemate
equilibrium of 0.001 at time zero. The tumor shrinks slightly and there are oscillations around
the equilibrium value of T/T0 = 1.0. These non-intuitive results demonstrate sizeable oscillations
with a period of 500 days in which the tumor mass grows to a maximum and then shrinks
significantly. The immune response lags the tumor response in phase. In Figures 2(c) and 2(d)
the oscillations gradually amplify until around 1800 days. Then the lymphocyte population
finally grows beyond the threshold level near 0.015, which is sufficient to win the battle and kill
the tumor completely.

Importance of the initial immune response
There are more anomalies, including the paradoxical result of success at very low L0/T0 =
0.0000001 (Figure 3). This value is several orders of magnitude less than the value 0.001 at
steady state equilibrium. Now the tumor grows freely and quickly at first and doubles in size.
Then it provokes a suprathreshold immune response that kills the last tumor cell at 264 days.
Such dynamics are not generally seen with conventional anti-cancer chemotherapy.
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Figure 3. Time histories of (a) tumor and (b) lymphocyte cell numbers in an extreme case of
pseudoregression. Initial immune response is too weak to impact tumor growth, but after
doubling of tumor cell mass the cell-cell signaling provokes a large and lethal immune
response.
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Figure 4. Time histories of (a) tumor and (b) lymphocyte cell numbers in a rare case of
partial response followed by extreme pseudoregression and ultimate tumor elimination after
two years.
In Figure 4 with L0/T0 = 0.00003 (greater than the value in Figure 3) the initial tumor growth
produces a strong response but not quite sufficient completely destroy the tumor. Regrowth
happens until there is more than doubling of T0, whereupon a lymphocyte population well over 1
in 100 tumor cells rises up to produce a complete cure, but only after 30 months of treatment. In
3
this case the maximal diameter ratio, dmax/d0  √2.5  1.34.
In general, for a tumor model of a particular growth rate, g, success vs. failure is strongly
influenced by differences in the initial immunocyte population size, L0/T0 , over many orders of
magnitude. Figure 5 shows the time course of tumor diameter for the otherwise standard model
of Table 1 for each of several initial lymphocyte populations ranging over 8 orders of magnitude,
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representing severely immunodeficient vs. strongly immunocompetent individuals. The models
predict surprising and paradoxical responses that have also been observed in the clinic (see
Discussion) and depend on particular kinetic interactions. The horizontal line labeled L0/T0 =
0.001 in Figure 5 indicates the stalemate condition of Table 1. If the initial immune response is
either strengthened or weakened by one order of magnitude, oscillations over a 2 to 4 year time
course happen, similar to those in Figure 2. However, if the initial lymphocyte population is
reduced by 3 to 7 orders of magnitude, there is initial tumor diameter growth by about 1.3 to 1.5
fold, which is followed by rapid tumor cell killing and tumor elimination in less than 1 year.
2
1.8

L0/T0 = 0.01

1.6

L0/T0 = 0.001

Diameter ratio (d/d0)
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0.2
L0/T0 = e-10
0
0

500

1000

1500

Time of follow up (days)

Figure 5. Simulated histories of tumor size after onset of immunotherapy for various values
of L0/T0 , illustrating paradoxical effects of initial immune cell population size.

In the forgoing simulations, the tumor cells are constantly susceptible to cytotoxic cells with no
development of resistance or tumor escape mechanisms. The exponential phases of growth are
not related to tumor cell heterogeneity or evolution of resistant strains(12, 23), but to the
underlying kinetics of predator-prey equations(5, 6). With fewer lymphocytes at time zero more
tumor growth is needed to provoke an intense, and ultimately successful, anti-tumor immune
response.
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Histograms of successful vs. failed treatments
Figure 6 shows histograms of tumor diameter ratios for failed and successful courses of
immunotherapy in a heterogeneous set of 4000 simulated patients having variations in model
parameters, as shown in Table 2. The figures show the statistical distributions of d/d0 values
observed at either 2, 4, 6, 8, 10, or 12 months follow up along the horizontal axes and the
corresponding probability density functions on the vertical axes. The probability density
function (pdf) is scaled by sample size, such that the area under each pdf curve is exactly 1.00.
Circles represent d/d0 values for failed treatments, according to the criteria listed previously.
Squares represent d/d0 values for successful treatments. At 2 months follow up, most cases show
little change in diameter with d/d0 near 1, except for a few treated cases with rapid shrinkage and
d/d0 near zero. At 4 and 6 months follow up, greater proportions of treated cases shrink toward
zero diameter. At 8 and 12 months follow up, most successful cases show tumor regression, but
a few remain near their original size or larger. At 8 and 12 months follow up, failed cases show
a wide range of sizes, with some partially regressing and some cases continuing to grow.
Importantly, in this particular model the distributions of successful and failed cases begin to
separate as follow up continues. The completeness of the separation improves over time.
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Figure 6. Histograms, scaled as probability density for easy comparison, of simulated
successful and failed immunotherapy treatments based on predator-prey kinetic Equations (1)
and (2). Square data points represent distributions of successful cases of tumor elimination
within 2 years and circles represent distributions of failed cases of true progressive disease.
Areas under the curves of all histograms are 1.00. Dashed lines represent decision thresholds
for apparent progressive disease using a raised bar strategy, in which the bar is raised to 2.0
for the first 6 months of follow up and then lowered to 0.5.

The vertical dashed lines in Figure 6 represent a simple step-down protocol, in which a decision
threshold of 2.0 is used for the first 6 months of follow up and then adjusted downward to 0.5
after 6 months. In the standard or reference protocol any increase in tumor diameter is
considered as evidence of progression, with a constant decision threshold for progressive disease
of d/d0 = 1.0. The step-down paradigm eliminates many false alarms that could curtail ultimately
successful therapy.

DISCUSSION
Compared to conventional chemotherapy, immunotherapy for cancer has very different kinetics
that involve building an immune response (k and ) from wide-ranging starting conditions.
Several months are often required for an adequate T cell population explosion and for homing
and infiltration of the tumor, after which there is therapeutic tumor cell killing. In clinical
practice both physicians and patients, who are accustomed to the kinetics of conventional cancer
chemotherapy, may be tempted to stop too soon. Better knowledge of immune response kinetics
may allow better planning of clinical trials and better individual patient care to account for early,
clinically insignificant progressive disease or “pseudoprogression”(7, 22, 33).
Mathematical models such as the one described here can help to explain the, complex, dynamical
behavior of anti-tumor immunity(9, 24, 29, 43). The simplicity of Equations (1) and (2) encodes
many emergent behaviors in the battle between immunocytes and cancer cells, including
oscillations in tumor cell numbers, sharp thresholds between failed and completely successful
therapy, improved success after weakening of anti-tumor response parameters, and initial tumor
growth as a prelude to early tumor elimination. The variable histories of changes in tumor size
simulated here (Figures 1 to 5) and previously(3), are similar to those observed in patients with
malignant melanoma treated with anti-cytotoxic T lymphocyte-associated protein 4
immunotherapy (ipilimumab)(22). Present results suggest that growth or oscillations in tumor
size after manipulation of the immune system need not imply selective resistance, escape
mechanisms, or heterogeneity of the tumor cell population. Some initial tumor growth after
treatment begins may simply reflect the nature of a predator-prey-like system. A very small
initial population of lymphocytes can be sufficient to start a positive feedback cycle that
ultimately results in tumor elimination, provided sufficient time is allowed for immune cell
recruitment.
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The kinetics of Equations (1) and (2) predict interesting apparent paradoxes that may explain
treatment failures in early trials of immunotherapy. As shown previously by Babbs(3) and in
Figure 1, a form of cyclic pseudoprogression can occur in which the tumor diameter alternately
grows and shrinks for several cycles prior to a final stage of growth, which is followed by
massive tumor cell kill. Such swings are an expected mathematical property of negative
feedback control and not necessarily a sign of an incorrect hypothesis, sloppy technique, or
human error. The rare cases in which tumor cell populations oscillate with increasing peak
values are reminiscent of the phenomenon of concomitant tumor immunity mediated by a CD-8
T-cell response, in which challenge with a second tumor implant of the same type can stimulate
immune rejection(16). Such unpredictability of dynamic interactions between immune response
and tumor may mean that personalized patient specific strategies will be needed to achieve
maximal success. Here computer simulations and models can help.
The concept of raising the bar for definition of progressive disease may provide practicing
clinicians and their patients with useful guides to monthly management of immune therapy and
the necessary encouragement to patiently wait for the immune treatment to work in its own
characteristic way. Necessary data are tumor size vs. time curves from imaging studies that are
already recommended for follow up in immunotherapy(22, 31). Aggregation of d/d0 data from
multiple imaging findings can reduce the average measurement error or “noise”, which declines
as a function of 1/√𝑛 , where n is the number of tumor nodules measured. By monitoring
tumor diameter growth versus time and using a raised threshold for defining progression during
the first six months of follow up, one can accommodate expected initial growth in tumor size, as
the lymphocytic response grows. This simple adjustment eliminates many false alarms signaling
progressive disease, which in the setting of conventional chemotherapy would be of concern.
Here a “raised bar” to 2.0 times original diameter (larger than the 1.2 threshold value
recommended by Nishino et al.(31)) is shown to have a roughly optimal result on prediction
accuracy, with little downside cost.

Limitations and future work
The present model includes only two differential equations and a handful of parameters. This is
clearly an oversimplification. The complexity of immune mechanisms is well known(32). There
are a host of T cell types, T cell exhaustion, pro-tumorigenic subsets of immune cells,
checkpoints and checkpoint inhibitors, interactions with neutrophils and macrophages, and
interactions with dendritic cells and myeloid-derived suppressor cells resulting in positive and
negative feedback loops within the immune system, to name a few(7). Yet what is remarkable
from the present study is how just two ordinary differential equations with lumped parameters
can mimic the kinetics of immunotherapy of cancer to a reasonable degree--perhaps a rare case
of the “less is more” principle.
Different initial levels of a raised bar may apply to different tumor types and stages. The present
study focuses on one generic cancer type to illustrate proof of concept. However, the model and
approach described here may well be applicable across a wide range of cancer types, as
suggested by Seymour(36). Model parameters can be adjusted to fit different malignant
diseases. Further, there is the added potential for tuning the parameters to make of the present
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model patient specific. The value of g can be customized based on the patient’s individual
history. The value of L0/T0 can be customized based on individual biopsy results(10, 11, 28, 39).
Perhaps in vitro tests could be done from biopsy material to estimate constants k and .
Personalized values of  might be estimated, based on specific biomarkers and adjusted for
various immunotherapy combinations.
Here a general mathematical model is developed to describe the basic time-varying relationships
of cancer, immunity, and immunotherapy. In the future patient specific parameters can be
substituted for the general ones to create truly personalized models using Equations (1) and (2) in
which the parameters are time-varying and adjusted to reflect changes in dosage, the use of
adjuvants, or evolution of resistant tumor cell lines, combinations of conventional chemotherapy
and immunotherapy(1, 8, 15), combinations of radiation and immunotherapy(18), as well as
variability of cancer types and stages, prior treatments, and evolving mutations(40), conventional
chemotherapy or radiation followed by immunotherapy(20, 41), targeted radiation to specific
tumor masses that spares systemic damage to the patient’s immune system, dose fractionation
schemes, occasional drug holidays, etc. Adoptive immunotherapy(24, 30, 34), for example, can
be simulated by a boost in L0. Adjunctive treatment with immune modifiers such as
imiquimod(35) can be represented by a boost in . Another strategy to increase  might be to
reduce the level of suppressive cells (Treg and myeloid-derived suppressor cells) (1).
Supplemental radiation treatment can be represented approximately by temporarily replacing the
positive growth constant, g, with a negative value, so that each cell cycle would then lead to
death rather than replication. Many such scenarios are open to investigation. The present model
might help to predict especially promising ones for future laboratory or clinical testing.

DISCLOSURE OF INTEREST
The author reports no conflict of interest.

FUNDING DETAILS
This work was supported by Purdue University internal funds.

18

REFERENCES
1.
2.

3.
4.

5.
6.
7.

8.

9.

10.

11.

12.
13.
14.

15.

Abastado JP. The next challenge in cancer immunotherapy: controlling T-cell traffic to
the tumor. Cancer research 72: 2159-2161, 2012.
Agur Z, Halevi-Tobias K, Kogan Y, and Shlagman O. Employing dynamical
computational models for personalizing cancer immunotherapy. Expert Opin Biol Ther
16: 1373-1385, 2016.
Babbs CF. Predicting success or failure of immunotherapy for cancer: insights from a
clinically applicable mathematical model. Am J Cancer Res 2: 204-213, 2012.
Balwit JM, Hwu P, Urba WJ, and Marincola FM. The iSBTc/SITC primer on tumor
immunology and biological therapy of cancer: a summary of the 2010 program. J Transl
Med 9: 18, 2011.
Bell G. Predator-prey equations simulating an immune response. Mathematical
Biosciences 16: 291-314, 1973.
Berryman AA. The origins and evolution of predator-prey theory. Ecology 73: 15301535, 1992.
Champiat S, Ferrara R, Massard C, Besse B, Marabelle A, Soria JC, and Ferte C.
Hyperprogressive disease: recognizing a novel pattern to improve patient management.
Nat Rev Clin Oncol 15: 748-762, 2018.
Copier J, Dalgleish AG, Britten CM, Finke LH, Gaudernack G, Gnjatic S, Kallen K,
Kiessling R, Schuessler-Lenz M, Singh H, Talmadge J, Zwierzina H, and Hakansson
L. Improving the efficacy of cancer immunotherapy. Eur J Cancer 45: 1424-1431, 2009.
De Boer RJ, Hogeweg P, Dullens HF, De Weger RA, and Den Otter W. Macrophage
T lymphocyte interactions in the anti-tumor immune response: a mathematical model. J
Immunol 134: 2748-2758, 1985.
Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, Budczies J, DarbEsfahani S, Kronenwett R, Hanusch C, von Torne C, Weichert W, Engels K,
Solbach C, Schrader I, Dietel M, and von Minckwitz G. Tumor-associated
lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in
breast cancer. J Clin Oncol 28: 105-113, 2010.
Djenidi F, Adam J, Goubar A, Durgeau A, Meurice G, de Montpreville V, Validire
P, Besse B, and Mami-Chouaib F. CD8+CD103+ tumor-infiltrating lymphocytes are
tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung
cancer patients. J Immunol 194: 3475-3486, 2015.
Drake CG, Jaffee E, and Pardoll DM. Mechanisms of immune evasion by tumors.
Advances in immunology 90: 51-81, 2006.
Euvrard S, Kanitakis J, and Claudy A. Skin cancers after organ transplantation. The
New England journal of medicine 348: 1681-1691, 2003.
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C,
Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc
PH, Trajanoski Z, Fridman WH, and Pages F. Type, density, and location of immune
cells within human colorectal tumors predict clinical outcome. Science (New York, NY
313: 1960-1964, 2006.
Gatenby RA. Application of competition theory to tumour growth: implications for
tumour biology and treatment. Eur J Cancer 32A: 722-726, 1996.
19

16.
17.

18.

19.
20.

21.
22.

23.

24.
25.

26.

27.

28.

29.
30.

Gershon RK, Carter RL, and Kondo K. On concomitant immunity in tumour-bearing
hamsters. Nature 213: 674-676, 1967.
Gooden MJ, de Bock GH, Leffers N, Daemen T, and Nijman HW. The prognostic
influence of tumour-infiltrating lymphocytes in cancer: a systematic review with metaanalysis. British journal of cancer 105: 93-103.
Gough M, Sharon S, Crittenden M, and Young K. Using Preclinical Data to Design
Combination Clinical Trials of Radiation Therapy and Immunotherapy. Semin Radiat
Oncol 30: 158-172, 2019.
Hanahan D, and Weinberg RA. Hallmarks of cancer: the next generation. Cell 144:
646-674, 2011.
Harris TJ, Hipkiss EL, Borzillary S, Wada S, Grosso JF, Yen HR, Getnet D, Bruno
TC, Goldberg MV, Pardoll DM, DeWeese TL, and Drake CG. Radiotherapy
augments the immune response to prostate cancer in a time-dependent manner. The
Prostate 68: 1319-1329, 2008.
Hoos A, and Britten C. The immuno-oncology framework: Enabling a new era of
cancer therapy. Oncoimmunology 1: 334-339, 2012.
Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey
R, Blumenstein B, Old L, and Wolchok J. Improved endpoints for cancer
immunotherapy trials. J Natl Cancer Inst 102: 1388-1397, 2010.
Kirkwood JM, Tarhini AA, Panelli MC, Moschos SJ, Zarour HM, Butterfield LH,
and Gogas HJ. Next generation of immunotherapy for melanoma. J Clin Oncol 26:
3445-3455, 2008.
Kirschner D, and Panetta JC. Modeling immunotherapy of the tumor-immune
interaction. Journal of mathematical biology 37: 235-252, 1998.
Kronik N, Kogan Y, Elishmereni M, Halevi-Tobias K, Vuk-Pavlovic S, and Agur Z.
Predicting outcomes of prostate cancer immunotherapy by personalized mathematical
models. PLoS One 5: e15482, 2010.
Kronik N, Kogan Y, Vainstein V, and Agur Z. Improving alloreactive CTL
immunotherapy for malignant gliomas using a simulation model of their interactive
dynamics. Cancer Immunol Immunother 57: 425-439, 2008.
Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H,
Boezen HM, van der Zee AG, Daemen T, and Nijman HW. Prognostic significance of
tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage
ovarian cancer. Cancer Immunol Immunother 58: 449-459, 2009.
Mansuri N, Birkman EM, Heuser VD, Lintunen M, Algars A, Sundstrom J,
Ristamaki R, Lehtinen L, and Carpen O. Association of tumor-infiltrating T
lymphocytes with intestinal-type gastric cancer molecular subtypes and outcome.
Virchows Arch 478: 707-717, 2021.
Mohler RR, Asachenkov AL, and Marchuk GI. A systems approach to immunology
and cancer. IEEE Transactions on Systems, Man, and Cybernetics 24: 632-642, 1994.
Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal
RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR,
Rogers-Freezer LJ, Mavroukakis SA, and Rosenberg SA. Cancer regression in
patients after transfer of genetically engineered lymphocytes. Science (New York, NY
314: 126-129, 2006.
20

31.

32.
33.
34.

35.

36.

37.

38.

39.

40.
41.

42.

43.

Nishino M, Giobbie-Hurder A, Gargano M, Suda M, Ramaiya NH, and Hodi FS.
Developing a common language for tumor response to immunotherapy: immune-related
response criteria using unidimensional measurements. Clin Cancer Res 19: 3936-3943,
2013.
Pardoll D. Cancer and the Immune System: Basic Concepts and Targets for Intervention.
Seminars in oncology 42: 523-538, 2015.
Ribas A, Chmielowski B, and Glaspy JA. Do we need a different set of response
assessment criteria for tumor immunotherapy? Clin Cancer Res 15: 7116-7118, 2009.
Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME,
Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS,
Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL,
Laurencot C, and Rosenberg SA. Tumor regression in patients with metastatic synovial
cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NYESO-1. J Clin Oncol 29: 917-924.
Ryu J, and Yang FC. A review of topical imiquimod in the management of basal cell
carcinoma, actinic keratoses, and other skin lesions. Clinical Medicine: Therapeutics 1:
1557-1575, 2009.
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU,
Litiere S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK,
Wolchok JD, Ballinger M, Caramella C, de Vries EGE, and group Rw. iRECIST:
guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol
18: e143-e152, 2017.
Starzi TE, Porter KA, Iwatsuki S, Rosenthal JT, Shaw BW, Atchison RW, Nalesnik
MA, Ho M, Griffith BP, Hakala TR, Hardesty RL, Jaffee R, and Bahnson HT.
Reversibility of lymphomas and lymphoproliferative lesions developing under
cyclosporin-steroid therapy The Lancet 322: 583-587, 1984.
Tat D, Polenakovik H, and Herchline T. Comparing interferon- gamma release assay
with tuberculin skin test readings at 48-72 hours and 144-168 hours with use of 2
commercial reagents. Clin Infect Dis 40: 246-250, 2005.
Tokito T, Azuma K, Kawahara A, Ishii H, Yamada K, Matsuo N, Kinoshita T,
Mizukami N, Ono H, Kage M, and Hoshino T. Predictive relevance of PD-L1
expression combined with CD8+ TIL density in stage III non-small cell lung cancer
patients receiving concurrent chemoradiotherapy. Eur J Cancer 55: 7-14, 2016.
Ventola CL. Cancer Immunotherapy, Part 3: Challenges and Future Trends. P T 42: 514521, 2017.
Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen HR, Goldberg MV, Grosso JF,
Getnet D, Demarzo AM, Netto GJ, Anders R, Pardoll DM, and Drake CG.
Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate
cancer model. Cancer research 69: 4309-4318, 2009.
Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M,
Bohnsack O, Nichol G, Humphrey R, and Hodi FS. Guidelines for the evaluation of
immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer
Res 15: 7412-7420, 2009.
Zhivkov P, and Waniewski J. Modelling tumour-immunity interactions with different
simulation functions. Int J Appl Math Comput Sci 13: 307-315, 2003.
21

